Key result
Epicardial adipose tissue is evaluated as a potential early, noninvasive biomarker for cardiovascular disease and risk stratification in patients with renal disease.
Why the study?
Cardiovascular morbidity and mortality in renal disease are high, but concrete evidence and societal guidelines to detect early CVD in this population remain scarce.
Can epicardial adipose tissue serve as a reliable, early, noninvasive biomarker for cardiovascular disease in patients with renal disease?
Population
Patients with renal disease
Design
Clinical review
Authors
Loading...
EAT's paracrine effects on cardiac function remain hypothesis-generating; leaves open its therapeutic targeting pending prospective validation.
Can epicardial adipose tissue serve as a reliable, early, noninvasive biomarker for cardiovascular disease in patients with renal disease?
This review highlights the potential of epicardial adipose tissue as an early, noninvasive biomarker for cardiovascular risk stratification in patients with renal disease.
Aeddula et al. (2019) conducted a review in Renal disease. Epicardial Adipose Tissue (EAT) was evaluated. Epicardial adipose tissue is evaluated as a potential early, noninvasive biomarker for cardiovascular disease and risk stratification in patients with renal disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: